FDA Clears Redesigned Mammography System from Siemens Healthineers
In addition to full-field digital mammography and titanium contrast-enhanced mammography capabilities, the Mammomat B.brilliant system also offers ergonomic, workflow and patient comfort benefits.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Mammomat B.brilliant, a redesigned mammography device that reportedly features improved ergonomics, workflow enhancements and key aspects targeting patient comfort.
The system’s laser positioning guide and curved breast compression paddles facilitate optimal breast positioning and improved consistency with image quality, according to Siemens Healthineers, the manufacturer of Mammomat B.brilliant. To further address the bending and twisting that can occur with patient positioning, the company said the automated ComfortMove feature with the Mammomat B.brilliant system allows tube head movement that is independent of the bucky.
Siemens Healthineers said the Mammomat B.brilliant mammography system features cleared elements with respect to full-field digital mammography, titanium contrast-enhanced mammography (CEM) and breast biopsy procedures. (Image courtesy of Siemens Healthineers.)
Siemens Healthineers said the system also features cleared elements with respect to full-field digital mammography, titanium contrast-enhanced mammography (CEM) and breast biopsy procedures.
“With the 510(k) clearance of the Mammomat B.brilliant, Siemens Healthineers proudly introduces completely new mammography technology to the market,” said Niral Patel, vice president of X-ray products at Siemens Healthineers North America. “We believe more women deserve access to next-generation screening technology, and this innovation underlies our commitment to women’s health.”
Another feature, PlatinumTomo, a 3D tomosynthesis volume acquisition technology, is pending FDA review, according to Siemens Healthineers. The company added that the PlatinumTomo feature is currently available in Asia, Europe, and South America.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
